Abstract
Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
CNS & Neurological Disorders - Drug Targets
Title: Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
Volume: 10 Issue: 3
Author(s): Anne Penttinen, Jofre Tenorio-Laranga, Anssi Siikanen, Markus Morawski, Steffen Roßner and J. Arturo Garcia-Horsman
Affiliation:
Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus
Abstract: Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.
Export Options
About this article
Cite this article as:
Penttinen Anne, Tenorio-Laranga Jofre, Siikanen Anssi, Morawski Markus, Roßner Steffen and Arturo Garcia-Horsman J., Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research, CNS & Neurological Disorders - Drug Targets 2011; 10(3) . https://dx.doi.org/10.2174/187152711794653742
DOI https://dx.doi.org/10.2174/187152711794653742 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clozapine Safety, 40 Years Later
Current Drug Safety Altered CYP Expression and Function in Response to Dietary Factors: Potential Roles in Disease Pathogenesis
Current Drug Metabolism Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology The Application of Chitosan and Its Derivatives as Nanosized Carriers for the Delivery of Chemical Drugs and Genes or Proteins
Current Drug Targets Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
Current Drug Safety Monobactams: A Unique Natural Scaffold of Four-Membered Ring Skeleton, Recent Development to Clinically Overcome Infections by Multidrug- Resistant Microbes
Letters in Drug Design & Discovery Therapeutic Prospects for Parathyroid Hormone and Parathyroid Hormone Analogs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents An Overview on Natural Cholinesterase Inhibitors - A Multi-Targeted Drug Class - and Their Mass Production
Mini-Reviews in Medicinal Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Effects of N-Acetyl-L-Cysteine and Hyaluronic Acid on HBOC-201- Induced Systemic and Cerebral Vasoconstriction in the Rat
Current Drug Discovery Technologies Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology Novel Insight into the Inflammatory and Cellular Responses Following Experimental Glaucoma Surgery: A Roadmap for Inhibiting Fibrosis
Current Molecular Medicine Monoamino Oxidase A: An Interesting Pharmacological Target for the Development of Multi-Target QSAR
Mini-Reviews in Medicinal Chemistry Role of Ascorbic Acid in Cardiovascular Performance During Acute Hemorrhage
Vascular Disease Prevention (Discontinued) Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors
Current Enzyme Inhibition The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Topics in Medicinal Chemistry Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry